0.6927
Pds Biotechnology Corp Aktie (PDSB) Neueste Nachrichten
PDS Biotechnology Corp (PDSB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PDS Biotechnology Corp (PDSB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PDS Biotechnology Corp (PDSB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.699|Chg%:+0.017 - TradingKey
PDS Biotechnology Corp (PDSB) Balance Sheet - TradingKey
PDS Biotechnology Corp (PDSB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
PDS Biotechnology Corp (PDSB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.720|Chg%:+0.039 - TradingKey
PDSB|PDS Biotechnology Corp|Price:0.681|Chg%:-0.019 - TradingKey
PDS Biotechnology Corp. Revenue Breakdown – FWB:EU6 - TradingView
PDS Biotechnology Corp (PDSB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PDS Biotechnology Corp SEC Filing (Jul 22, 2026) - Stock Titan
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight - GlobeNewswire Inc.
Form S-3 PDS Biotechnology Corp For: 10 July By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ: PDSB) registers 13.3M shares tied to note and warrant deal - Stock Titan
PDSB | PDS Biotechnology Corporation Common Executive Compensation - Quiver Quantitative
PDS Biotechnology (PDSB) Hovers Near Support Amid Modest DeclineVolume Breadth - dars.gov.et
PDS Biotechnology Corp (PDSB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PDS Biotechnology (NASDAQ: PDSB) details 2026 proxy votes and pay - Stock Titan
PDS Biotechnology Corp. Actuals & Estimates (NASDAQ:PDSB) - TradingView
PDS Biotechnology Corp. Actuals & Estimates (DUS:EU6) - TradingView
PDSB Forecast — Price Target — Prediction for 2027 - TradingView
PDS Biotech’s Double Squeeze: Nasdaq Clock Ticking as Equity Dilution Looms - AD HOC NEWS
PDS Biotechnology Corp (PDSB) Institutional Confidence - TradingKey
PDS Biotechnology Corp (PDSB) Valuation: PE, PB & Fair Value Analysis - TradingKey
PDS Biotechnology Closes Financing and Retires Convertible Debentures - TipRanks
PDS Biotechnology (NASDAQ: PDSB) launches $50M ATM program tied to YA II financing - Stock Titan
[PRE 14A] PDS Biotechnology Corp Preliminary Proxy Statement - Stock Titan
PDS Biotechnology (NASDAQ: PDSB) adds $6M note and $50M at-the-market stock program - Stock Titan
PDS Biotechnology schedules 2026 annual meeting for Aug. 10; stockholder proposal deadline set - TradingView
PDS Biotechnology (PDSB) schedules 2026 annual meeting and sets June 25 proposal cutoff - Stock Titan
PDS Biotechnology establishes up to $50M stock offering program - scanx.trade
PDSB Q1 2026 Earnings: EPS Beat Fails to Lift Shares as Pipeline Progress AwaitedROA Comparison - dars.gov.et
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - MSN
PDS Biotechnology Corporation - MLQ.ai
PDS Biotechnology Stock Gets Nasdaq Extension as Traders Eye PDSB - Bez Kabli
PDS Biotechnology (NASDAQ: PDSB) back in compliance with Nasdaq $1.00 bid rule - Stock Titan
PDSB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Pipeline ProgressGuidance Upgrade Report - dars.gov.et
PDS Biotechnology (PDSB) Slides 3.6% as Stock Tests Key Support Near $1.02Breakaway Gap - The Legal Advocate
PDSB Q1 2026 Earnings: Narrower Loss Drives Positive EPS Surprise Amid Pre-Revenue PhaseHealthcare Earnings Report - dars.gov.et
PDSBPDS Biotechnology Corp Stock Price and Quote - Finviz
PDSB Q4 2025 Earnings Call Transcript - Yahoo Finance
PDS Biotechnology Q1 2026 Earnings: EPS Beat on Narrower Loss, Clinical Progress in FocusReturn On Capital - Newser
PDS Biotechnology (PDSB) Edges Higher by 1.82% as Biotech Speculative Interest PersistsIron Condor Alert - dars.gov.et
PDS Biotechnology Q1 2026 Earnings: Narrowed Loss Per Share and Clinical Progress Drive Positive Market ResponseGrowth Acceleration Report - thelegaladvocate.com
PDS Biotechnology Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock Up 3.45%Earnings Growth Forecast - Newser
PDS Biotechnology Q1 2026 Earnings: EPS Beat Highlights Progress Despite Pre-Revenue StatusEarnings Forecast Report - newsline.com
PDS (PDSB) Q1 2026 Beat: Revenue $N/A, EPS Exceeds by SignificantPositive Surprise Momentum - The Legal Advocate
ETFs Investing in PDS Biotechnology Corp. Stocks - TradingView
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):